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Background. Trypanosoma is a genus of unicellular parasitic ﬂagellate protozoa. Trypanosoma brucei species and Trypanosoma
cruzi are the major agents of human trypanosomiasis; other Trypanosoma species can cause human disease, but are rare. In March
2015, a 38-year-old woman presented to a healthcare facility in southern Vietnam with fever, headache, and arthralgia. Microscopic
examination of blood revealed infection with Trypanosoma.
Methods. Microscopic observation, polymerase chain reaction (PCR) ampliﬁcation of blood samples, and serological testing
were performed to identify the infecting species. The patient’s blood was screened for the trypanocidal protein apolipoprotein L1
(APOL1), and a ﬁeld investigation was performed to identify the zoonotic source.
Results. PCR ampliﬁcation and serological testing identiﬁed the infecting species as Trypanosoma evansi. Despite relapsing 6
weeks after completing amphotericin B therapy, the patient made a complete recovery after 5 weeks of suramin. The patient was
found to have 2 wild-type APOL1 alleles and a normal serum APOL1 concentration. After responsive animal sampling in the pre-
sumed location of exposure, cattle and/or buffalo were determined to be the most likely source of the infection, with 14 of 30 (47%)
animal blood samples testing PCR positive for T. evansi.
Conclusions. We report the ﬁrst laboratory-conﬁrmed case of T. evansi in a previously healthy individual without APOL1 de-
ﬁciency, potentially contracted via a wound while butchering raw beef, and successfully treated with suramin. A linked epidemio-
logical investigation revealed widespread and previously unidentiﬁed burden of T. evansi in local cattle, highlighting the need for
surveillance of this infection in animals and the possibility of further human cases.
Keywords. Vietnam; zoonosis; Trypanosoma evansi; case investigation; emerging infections.
Southeast Asia is a hotspot for emerging and remerging infec-
tious diseases [1]. Over the last decade, Vietnam in particular
has been an epicenter for such infections [2]. The country has
a human population of >90 million, some of the highest densi-
ties of farmed livestock in Asia, and a substantial burden of in-
fectious diseases, many of which occur without an etiological
diagnosis [3]. More than half of Vietnam’s population resides
in rural areas, and most participate in small-scale animal
production, which likely facilitates the transfer of pathogens
from animals into humans (zoonotic transmission). Therefore,
we predict that zoonotic infections occur frequently in rural lo-
cations but do not trigger onward human-to-human transmis-
sion and often fail to be diagnosed [4]. Furthermore, because of
limited diagnostic capacity in provincial animal health facilities,
conclusive epidemiological investigations of zoonotic infections
in potential animal sources are expensive, challenging, and rare-
ly performed.
Trypanosoma is a genus of unicellular parasitic ﬂagellate pro-
tozoa within the class Kinetoplastida. The genus has several
members, the majority of which require transmission between
different hosts to complete their life cycle. Trypanosoma infec-
tions are responsible for a large burden of infectious disease in
humans globally [5]. The major zoonotic parasites, Trypano-
soma brucei species (T. brucei subspecies gambiense and T. bru-
cei subspecies rhodesiense) and Trypanosoma cruzi cause a
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substantial burden of sleeping sickness and Chagas disease in
sub-Saharan Africa and Latin America, respectively. Other Try-
panosoma species, such as T. lewisi, T. brucei subspecies brucei,
T. congolense, and T. evansi, can also cause disease in humans,
but are rare [6]. The majority of these atypical human cases of
Trypanosoma infections are due to T. lewisi and T. evansi. Try-
panosoma lewisi is a ubiquitous, nonpathogenic parasite of rats,
and is considered to be a human pathogen, although there have
been only a limited number of reported cases [7].Trypanosoma
evansi is associated with acute disease in camels and horses
(surra) and chronic disease in cattle and buffalo, and can be
found in South America, North Africa, the Middle East, and
South and Southeast Asia [8].
The only human case of T. evansi with molecular conﬁrma-
tion of the infecting species occurred in India in 2005 [9]. This
patient had a deﬁciency of apolipoprotein L1 (APOL1) [10], a
component of human serum with trypanocidal activity [11].
Four other probable cases have been reported worldwide [8],
3 in India and 1 in Egypt, but molecular parasite speciation
was not performed. Here we describe a clinical, parasitological,
and epidemiological investigation of the ﬁrst conﬁrmed human
infection of T. evansi in a previously healthy individual without
APOL1 deﬁciency in Asia.
CASE REPORT
On 19March 2015, a 38-year-old Vietnamese woman presented
to a healthcare facility in Dong Nai province in southern
Vietnam (approximately 30 km east of Ho Chi Minh City)
with 18 days of fever, headache, and arthralgia. She did not
seek medical advice during this period but self-treated with an-
tipyretics. She worked in a footwear factory, had given birth on
23 November 2014, and was breastfeeding a healthy infant; her
past medical history was unremarkable with no known under-
lying medical condition. Her only account of recent travel was
to Krong Pac district in Dak Lak, a rural province in Vietnam’s
Central Highlands, from 8 February to 2 March, to visit relatives
over the lunar New Year holiday. She had never traveled outside
Vietnam.
On presentation at the provincial hospital, she was
treated presumptively for malaria with dihydroartemisinin-
piperaquine. The following day she remained febrile and was
transferred to the Hospital for Tropical Diseases (HTD) in
Ho Chi Minh City. On admission at HTD, she had a severe
headache but no additional neurological symptoms or signs,
and her Glasgow Coma Scale score was 15/15. Her temperature
was 39.5°C, respiratory rate was 22 breaths/minute, pulse was
100 beats/minute, and blood pressure was 110/70 mm Hg. Car-
diorespiratory examination was normal and abdominal exami-
nation revealed nontender hepatomegaly.
Initial blood tests showed pancytopenia and mild renal im-
pairment with raised liver aminotransferases and hypoalbumi-
nemia (Table 1); electrolytes, lactate dehydrogenase, creatine
phosphokinase, and troponin I were within normal ranges. Mi-
crobiological cultures performed on blood, urine, and cerebro-
spinal ﬂuid (CSF) did not produce any signiﬁcant growth; CSF
cell count, protein, and glucose concentrations were within nor-
mal ranges. Serological tests for hepatitis B, hepatitis C, and
human immunodeﬁciency virus were negative. A blood ﬁlm,
stained with Giemsa and examined by microscopy, was negative
for malaria; however, numerous unicellular ﬂagellate protozoa,
with the distinctive morphology of Trypanosoma and with an
estimated concentration of >50 000 parasites/µL, were identiﬁed
(Figure 1). Motile parasites were also observed by direct micro-
scopic examination of the blood (Supplementary Data). Chest
radiography and electrocardiography were normal, and abdom-
inal ultrasound conﬁrmed hepatomegaly (164 mm) and spleno-
megaly (117 mm).
First-line antitrypanosomal drugs (eg, pentamidine and sur-
amin) are not available in Vietnam. Consequently, the patient
was treated with amphotericin B (0.7 mg/kg/day) for 7 days,
Table 1. Timeline of the Clinical Laboratory Investigations and Results of a Human Trypanosoma evansi Infection—Vietnam, 2015
Test Normal Range First Admission First Discharge Second Admission Second Discharge Follow-up
Date . . . 19 March 28 March 15 May 12 June 13 July
WBC count, cells/µL 4500–11 000 1680 5250 3260 2880 4170
Neutrophil count, cells/µL 2000–7500 530 2226 1330 1630 2247
Hemoglobin, g/dL 12–16 7.7 12.2 7.2 10.7 12.5
Platelet count, ×109 cells/L 150–400 97 270 51 183 196
Procalcitonin, ng/mL <0.15 32.25 ND 43.7 ND ND
Creatinine, mmol/L 60–115 143 48 139 66 66
Ferritin, ng/mL 15–200 1453 368 291 ND ND
Albumin, g/L 35–55 26.1 42.8 24.7 38 ND
Bilirubin, µmol/L 5.1–20.5 7.9 2.9 61.4 8.2 ND
AST, U/L 0–35 78 27 89 20 18
ALT, U/L 0–35 449 40 186 22 19
Values outside the normal range are shown in bold.
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ND, not determined; WBC, white blood cell.
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due to its reported trypanocidal activity [12]. She was afebrile
after 12 hours of treatment. After 24 and 48 hours of treatment,
blood ﬁlms demonstrated a fall in trypanosoma parasitemia
from 11 880 parasites/µL to 5900 parasites/µL, respectively.
No parasites were observed in blood ﬁlms by the fourth day
of treatment. White blood cell and platelet counts improved,
while hemoglobin dropped to 6.6 g/dL. She was discharged
without symptoms and with normal blood values on the 10th
day after admission (Table 1). The patient was recalled for
follow-up 4 weeks after discharge; she remained asymptomatic
with normal blood values, and no parasites were visible upon
microscopy.
Six weeks after hospital discharge (15 May), the patient re-
turned to HTD with 2 days of fever, headaches, nausea, and vom-
iting. Blood tests again demonstrated pancytopenia, raised liver
enzymes, and hypoalbuminemia (Table 1). An ultrasound
showed hepatomegaly of 167 mm and splenomegaly of 126
mm, and a peripheral blood smear identiﬁed >70 000 parasites/
µL. CSF examination was normal. By this time, suramin had been
sourced from the World Health Organization (WHO), and she
was treated with 1 g weekly for 5 weeks. The fever resolved within
8 hours of the ﬁrst dose, and the blood smear was negative within
12 hours. The patient was discharged and completed suramin
treatment without complications. She was followed up monthly
for 6 months with repeated clinical examination and blood
ﬁlms. Further investigations to identify the infecting parasite,
the patient’s serological responses and susceptibility, and the po-
tential source were subsequently undertaken.
METHODS
Parasite Identiﬁcation and Genotyping
Subgenus identiﬁcation of the trypanosomes was performed by
morphology and morphometry under microscopic examination
of the parasite using Giemsa-stained blood smears. To detect par-
asite DNA in blood samples, the following primers were used for
polymerase chain reaction (PCR) ampliﬁcation: Tryp1 (generic
for trypanosomes) [13], NRP and TBR (Trypanozoon subgenus)
[14], EVA [15], TEPAN [16], TE2249/50 [17], RoTat1.2 F/R [18]
(T. evansi/T. equiperdum speciﬁc), EVAB1/2 [19, 20] (T. evansi
type B speciﬁc), and Lew [21] (T. lewisi species speciﬁc). DNA
was extracted using the QIAamp DNA Blood Mini Kit (Qiagen)
following the manufacturer’s recommendations. PCR ampliﬁca-
tions were performed in volumes of 50 μL using ampliﬁcation
conditions described in the cited publications.
For parasite characterization, ampliﬁcation and sequencing
of a 234-bp polymorphic fragment of the small subunit (SSU)
18S ribosomal DNA (rDNA) was performed as previously
described [22]. Novel nucleotide sequences of the partial SSU
ribosomal RNA gene of Vietnamese T. evansi were deposited
in GenBank under the following accession numbers: KT844943,
T. evansi isolate T1 human Vietnam ﬁrst infection; KT844944,
T. evansi isolate T2 cattle Vietnam; KT844945, T. evansi isolate
T3 cattle Vietnam; and KT844946, T. evansi isolate T4 human
relapse Vietnam.
Serological Testing
The card agglutination test T. evansi (CATT/T. evansi) (Insti-
tute of Tropical Medicine, Antwerp, Belgium) is for the sero-
diagnosis of animal trypanosomiasis caused by T. evansi [23],
and can detect anti–T. evansi antibody in blood, serum, and
plasma [24]. Assays were performed following the manufactur-
er’s recommendations (serum dilution 1:4), and positive serum
samples were further tested in serial dilutions to provide a semi-
quantitative estimate of anti–T. evansi antibody in the patient’s
serum. A previously described T. evansi enzyme-linked immu-
nosorbent assay (ELISA) was also performed using the ﬁrst pa-
tient sample as positive control [25].
Figure 1. Giemsa-stained blood sample showing Trypanosoma evansi in the blood of a 38-year-old Vietnamese woman at ×100 (A) and ×1000 (B) magnification, with typical
forms of the subgenus Trypanozoon parasites (total length 20–30 µm, free flagellum, central nucleus, large undulating membrane, subterminal small kinetoplastids [<0.8 µm],
and a sharp posterior extremity).
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APOL1 Testing
The patient underwent APOL1 genotyping using targeted PCR
ampliﬁcation and sequencing as previously described [10].
Total genomic DNA was extracted from blood samples using
the Nucleon Genomic DNA Extraction Kit (GE Healthcare).
PCR was used to amplify the APOL1 gene using the primers
F-5′ AGCCACCACACCGAGCCAAAACTGC and R-5′ AG
CACAAGAAAGAAGCTTACAGGGG to amplify a 783-bp re-
gion of APOL1 on chromosome 22q13.1. PCR amplicons were
cloned into pCR2.1R Topo and sequenced in both directions
using BigDye sequencing on an ABI3700XL DNA sequencer
(Applied Biosystems). Quantitative Sandwich ELISAs (USCN
Life Sciences) were performed in duplicate according to the
manufacturer’s instructions to measure the concentration of
APOL1 in patient serum and the serum of 12 healthy anony-
mous Vietnamese volunteers.
Field Investigation
We conducted a census of cattle and buffalo farms located with-
in a 0.5-km radius of the patient’s relatives’ household. From
each sampled animal, blood was collected by ear puncture
and from the jugular vein into ethylenediaminetetraacetic acid
(EDTA) tubes. EDTA blood was used to prepare both thick and
thin blood smears that were ﬁxed and stained using Giemsa.
Buffy coat from centrifuged microcapillary tubes and Giemsa-
stained smears were examined at ×100 magniﬁcation for the
presence of trypanosomes. EDTA blood from the jugular vein
was centrifuged and the buffy coat and plasma were separated;
the former was used for molecular testing, and the latter for se-
rological testing. Rats were trapped on several of the sampled
farms, and blood samples were tested by serology and PCR am-
pliﬁcation. Staff from the sub–Department of Animal Health
and the Regional Animal Health Laboratory performed the an-
imal sampling. Serological tests were performed using CATT on
plasma from all species; ELISAs were performed on bovids only.
Ethical Approval
Written informed consent was obtained from the patient involved
in this investigation. Permission for the ﬁeld investigation was
covered by existing protocols for an ongoing study of zoonotic
infections in Vietnam (VIZIONS) [4], which were approved by
HTD and the Oxford Tropical Research Ethics Committee.
RESULTS
Patient Serological Response, Trypanosoma Identiﬁcation, and APOL1
Testing
Six plasma samples from the patient (primary presentation, re-
lapse, and late follow-up) gave positive agglutinations using the
CATT/T. evansi test and were positive at >1:512, 1:256, and 1:16
dilutions on primary presentation, convalescence, and relapse,
respectively (Table 2). Posttreatment follow-up samples provid-
ed evidence for decreasing antibody concentrations, testing pos-
itive at 1:8, 1:8, and 1:4 dilutions at 1, 2, and 4 months after
treatment, respectively. Whole blood from the patient was addi-
tionally subjected to PCR ampliﬁcation to conﬁrm the infecting
species. The resulting ampliﬁcations tested positive for Trypa-
nozoon and for T. evansi, and negative for T. lewisi and T. evansi
type B (Table 2). It was concluded the patient was infected with
T. evansi type A [13].
The APOL1 concentration in the patient’s serum was 3394
ng/mL; the APOL1 concentrations in 12 healthy Vietnamese
volunteers ranged from 1056 to 7400 ng/mL (median, 3094
ng/mL [interquartile range, 2754–4611 ng/mL]). Furthermore,
the patient was conﬁrmed to have 2 wild-type APOL1 alleles
(ie, no mutations in codon 142 or 266) upon ampliﬁcation
and sequencing of the gene encoding APOL1 [10].
Field Investigation
Potential sources of Trypanosoma infection include horses, dogs,
cattle, and buffaloes. The patient did not report any direct contact
with animals while in Dak Lak province, but recollected buffalo
and cattle in the area. She did not recall any bites from animals or
insects, but did recollect inﬂicting a knife wound to her ﬁnger on
24 February while butchering locally reared raw beef.
A total of 10 cattle and buffalo farms were identiﬁed within a
0.5-km radius from the patient’s relatives’ household in Krong
Pac. These farms contained a total of 121 animals (37 chickens,
35 cattle, 27 buffaloes, 17 pigs, 4 dogs, and 1 cat) and 65 people
(Figure 2). Blood was taken from 22 randomly selected cattle
Table 2. Laboratory Confirmation of Trypanosoma evansi Infection—Vietnam, 2015
Date Sample Microscopy CATT CATT Titration
PCR Amplificationa
Tryp1 EVA NRP TE2249/50 Rotat TEPAN Lew
19 March First admission + +++ 1:512 + + + + + + −
21 April Follow-up − +++ 1:256 − − − − − − −
15 May Second admission + + 1:16 + + + + + + −
08 June Follow-up − + 1:8 − − − − − − −
20 July Follow-up − + 1:8 − − − − − − −
14 Sept Follow-up − + 1:4 − − − − − − −
Abbreviations: CATT, card agglutination test T. evansi; PCR, polymerase chain reaction.
a Tryp1 (generic for trypanosomes) [13], NRP and TBR (Trypanozoon subgenus) [14], EVA [15], TEPAN [16], TE2249/50 [17], RoTat1.2 F/R [18] (T. evansi/T. equiperdum specific), EVAB1/2 [19,
20] (T. evansi type B specific), and Lew [21] (T. lewisi species specific).
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and 8 buffaloes. On microscopic examination, 3 of 22 (14%)
blood samples from cattle on 3 different farms were found to
contain Trypanosoma species; parasites were not observed in
the blood of other animals.
PCR ampliﬁcation for trypanosomes was performed on tem-
plate DNA extracted from the blood of the sampled animals.
Nine of 22 (41%) and 5 of 8 (63%) blood samples from cattle
and buffalo, respectively, produced PCR amplicons indicative
of T. evansi infection. Furthermore, 17 of 22 (77%) cattle
blood samples and 6 of 9 (67%) buffalo blood samples had ap-
preciable antibody against T. evansi by CATT and/or ELISA.
Notably, on further questioning, farmers on 4 of 10 sampled farms
(including all 3 of the farms with cattle that had a microscopy-
conﬁrmed parasitemia) reported recent unexplained illness in
their cattle characterized by wasting, paralyzed limbs, and
death, again indicative of T. evansi infection.
A comparison between four 18S rDNA sequences that were
generated (2 from the patient’s blood and 2 from cattle) exhib-
ited 99.5% DNA homology over 234 bp. The 2 animal samples
were additionally PCR positive for Rotat1.2 and negative for
EVAB, thus suggesting T. evansi type A infection in both the pa-
tient and the sampled cattle.
DISCUSSION
We present the ﬁrst reported case of human T. evansi infection in
Southeast Asia. Trypanosoma evansi is a zoonotic parasite that
can be commonly found in bovine animals in tropical regions,
although human disease is exceptionally rare [6]. The patient de-
scribed here had no previously described immunological risk
factors for Trypanosoma infection. Two mutations within the
gene encoding apolipoprotein L1 (APOL1), in codons 142 and
266, have been previously associated with T. evansi susceptibility
in an Indian patient [10]. APOL1 is a ubiquitous component of
high-density lipoprotein found in plasma that kills trypanosomes
by lysosome swelling [26]. Our patient did not have the genetic
mutations associated with APOL1 deﬁciency, and serum concen-
trations were comparable to 12 healthy Vietnamese controls. An-
imal models suggest there may be other susceptibility factors to
Trypanosoma infections, including increased host arginase activ-
ity and nitric oxide bioavailability [27], defective type I interferon
responses, and deﬁciencies in the complement lectin pathway
factors [28,29]. The only identiﬁed risk factor was that the patient
was 2–3 months postpartum at the time of exposure, which is a
well-known risk factor for many infectious diseases.
There are no previous reports describing T. evansi treatment
with amphotericin B and, although administration here corre-
lated with defervescence and parasite clearance, it is difﬁcult to
conclude whether the drug or a natural immunological response
induced this. Data from a murine T. cruzi model suggested that
amphotericin B may have a trypanostatic action, but poor try-
panocidal activity [12].As our patient relapsed 6 weeks later, the
efﬁcacy of amphotericin B for T. evansi therapy remains ambig-
uous. Treatment with suramin, however, resulted in rapid and
prolonged cure. Suramin is currently the ﬁrst-line recommend-
ed treatment for early-stage T. b. rhodesiense and had been used
successfully in treating human T. evansi previously [9]. Our case
provides additional evidence for suramin’s effectiveness against
this parasite. Furthermore, a decrease in antibody response was
Figure 2. Map of sampled field location in Dak Lak province in central Vietnam. A, Map of Vietnam with the locations of Ho Chi Minh City, Dong Nai, and Dak Lak provinces
highlighted. B, Map of farms sampled in response to the human case of Trypanosoma evansi. The orange circle (A) shows the location of the patient’s house. The 10 sampled
farm locations are shown and coded as follows: white, no evidence of trypanosomes; yellow, polymerase chain reaction and/or serological evidence of T. evansi in cattle or
buffalo; red, microscopic evidence of Trypanosoma species in cattle or buffalo blood.
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also observed with CATT titers falling from 1:16 at the time of
the treatment to 1:4 four months after infection. However, this
CATT titer did not increase on relapse, suggesting a lack of im-
munoglobulin M on secondary parasitemia.
The rapid epidemiological investigation accompanying this
ﬁrst human T. evansi infection in Southeast Asia is testament
to Vietnam’s coordinated public and animal healthcare systems
and links between clinicians and researchers. The rapid testing
of >50 animals of different species in 10 different farms within a
0.5-km radius of the patient’s residence found that a substantial
proportion of bovids in the farms surrounding the patient’s
home had PCR-conﬁrmed T. evansi infection (77% of bovids
additionally had serological evidence of the infection). Further-
more, the parasites detected in the patient (primary infection
and relapse) and parasites identiﬁed in bovids were T. evansi
type A. Additional sequencing of the polymorphic fragment
of the SSU 18s rDNA demonstrated a high degree of homology
between the animal and human parasites, implicating local bo-
vids as the most likely source of the infection.
Trypanosoma evansi is known to be endemic in Vietnam, and
seroprevalences approaching 30% have been described in bovids
and horses in the Red River Delta; outbreaks in central and
southern Vietnam have been acknowledged within Vietnam
[30]. However, the magnitude of the problem in terms of geo-
graphic distribution and prevalence in cattle/buffalo in Vietnam
is currently undetermined and likely underestimated. The unex-
plained death of several bovines in the patient’s locality was like-
ly due to surra as indicated by the clinical signs and the
prevalence of T. evansi in these species; these ﬁndings also
imply that the parasite has been circulating undetected for
some time. The endemicity of T. evansi may have economic
consequences, but it also highlights the potential for further
human cases. The precise route of transmission in this patient
remains uncertain; however, direct inoculation through a hand
wound, as was described for the previous case in India [9], is the
most reasonable explanation.
In conclusion, we have described the ﬁrst human case of
T. evansi infection reported in Asia in a previously healthy
individual without APOL1 deﬁciency. Subsequent ﬁeld investi-
gations demonstrated a high prevalence of bovids in the imme-
diate environs of the patient with clinical and molecular
evidence of T. evansi infection. The infection was most probably
acquired through direct wound inoculation from meat of infect-
ed cattle. Further research is required to better understand this
zoonotic pathogen, including host susceptibility factors, poten-
tial vectors, and therapeutic options for both human and animal
infections.
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